118 related articles for article (PubMed ID: 18349123)
1. Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines.
Bock O; Höftmann J; Theophile K; Hussein K; Wiese B; Schlué J; Kreipe H
Am J Pathol; 2008 Apr; 172(4):951-60. PubMed ID: 18349123
[TBL] [Abstract][Full Text] [Related]
2. CCN2/CTGF expression does not correlate with fibrosis in myeloproliferative neoplasms, consistent with noncanonical TGF-β signaling driving myelofibrosis.
Leguit RJ; Broekhuizen R; de Witte M; Raymakers RAP; Goldschmeding R
Virchows Arch; 2024 May; 484(5):837-845. PubMed ID: 38602559
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies.
Zahr AA; Salama ME; Carreau N; Tremblay D; Verstovsek S; Mesa R; Hoffman R; Mascarenhas J
Haematologica; 2016 Jun; 101(6):660-71. PubMed ID: 27252511
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide DNA methylation profiling is able to identify prefibrotic PMF cases at risk for progression to myelofibrosis.
Lehmann U; Stark H; Bartels S; Schlue J; Büsche G; Kreipe H
Clin Epigenetics; 2021 Feb; 13(1):28. PubMed ID: 33541399
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis.
Lecomte S; Devreux J; de Streel G; van Baren N; Havelange V; Schröder D; Vaherto N; Vanhaver C; Vanderaa C; Dupuis N; Pecquet C; Coulie PG; Constantinescu SN; Lucas S
Blood; 2023 Feb; 141(5):490-502. PubMed ID: 36322928
[TBL] [Abstract][Full Text] [Related]
6. Fibrosis and bone marrow: understanding causation and pathobiology.
Ghosh K; Shome DK; Kulkarni B; Ghosh MK; Ghosh K
J Transl Med; 2023 Oct; 21(1):703. PubMed ID: 37814319
[TBL] [Abstract][Full Text] [Related]
7. Identity of Gli1
Sena IFG; Prazeres PHDM; Santos GSP; Borges IT; Azevedo PO; Andreotti JP; Almeida VM; Paiva AE; Guerra DAP; Lousado L; Souto L; Mintz A; Birbrair A
Exp Hematol; 2017 Oct; 54():12-16. PubMed ID: 28690072
[TBL] [Abstract][Full Text] [Related]
8. Circulating bone morphogenetic protein 1-3 isoform increases renal fibrosis.
Grgurevic L; Macek B; Healy DR; Brault AL; Erjavec I; Cipcic A; Grgurevic I; Rogic D; Galesic K; Brkljacic J; Stern-Padovan R; Paralkar VM; Vukicevic S
J Am Soc Nephrol; 2011 Apr; 22(4):681-92. PubMed ID: 21415150
[TBL] [Abstract][Full Text] [Related]
9. Bone Morphogenetic Proteins stimulate mammary fibroblasts to promote mammary carcinoma cell invasion.
Owens P; Polikowsky H; Pickup MW; Gorska AE; Jovanovic B; Shaw AK; Novitskiy SV; Hong CC; Moses HL
PLoS One; 2013; 8(6):e67533. PubMed ID: 23840733
[TBL] [Abstract][Full Text] [Related]
10. Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection.
Papadantonakis N; Matsuura S; Ravid K
Blood; 2012 Aug; 120(9):1774-81. PubMed ID: 22767499
[TBL] [Abstract][Full Text] [Related]
11. Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis.
Martinaud C; Desterke C; Konopacki J; Vannucchi AM; Pieri L; Guglielmelli P; Dupriez B; Ianotto JC; Boutin L; Lataillade JJ; Le Bousse-Kerdilès MC
Genom Data; 2015 Sep; 5():1-2. PubMed ID: 26484208
[TBL] [Abstract][Full Text] [Related]
12. Thrombopoietin mimetic-induced bone marrow fibrosis.
Harper K; Bagot C; Leach M; Bain BJ
Am J Hematol; 2024 Jan; 99(1):135-136. PubMed ID: 37950860
[No Abstract] [Full Text] [Related]
13. Editorial: Megakaryocytes as regulators of tumor microenvironments.
Migliaccio AR; Balduini A; Zhan H
Front Oncol; 2022; 12():1090658. PubMed ID: 36505825
[No Abstract] [Full Text] [Related]
14. Targeting bone marrow mechanosensation in myelofibrosis.
Vinchi F
Hemasphere; 2024 Mar; 8(3):e46. PubMed ID: 38501049
[No Abstract] [Full Text] [Related]
15. Transcriptomic comparison of bone marrow CD34 + cells and peripheral blood neutrophils from ET patients with JAK2 or CALR mutations.
Guijarro-Hernández A; Vizmanos JL
BMC Genom Data; 2023 Aug; 24(1):40. PubMed ID: 37550636
[TBL] [Abstract][Full Text] [Related]
16. Carbohydrates and ginsenosides in shenmai injection jointly improve hematopoietic function during chemotherapy-induced myelosuppression in mice.
Zhang S; Mi Y; Ye T; Lu X; Liu L; Qian J; Fan X
Chin Med; 2022 Nov; 17(1):124. PubMed ID: 36333798
[TBL] [Abstract][Full Text] [Related]
17. Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels.
Lewandowski K; Kanduła Z; Gniot M; Paczkowska E; Nawrocka PM; Wojtaszewska M; Janowski M; Mariak M; Handschuh L; Kozlowski P
Ann Hematol; 2022 Dec; 101(12):2665-2677. PubMed ID: 36266510
[TBL] [Abstract][Full Text] [Related]
18. Momelotinib: an emerging treatment for myelofibrosis patients with anemia.
Chifotides HT; Bose P; Verstovsek S
J Hematol Oncol; 2022 Jan; 15(1):7. PubMed ID: 35045875
[TBL] [Abstract][Full Text] [Related]
19. Primary Immune Thrombocytopenia and Essential Thrombocythemia: So Different and yet Somehow Similar-Cases Series and a Review of the Literature.
Sobas M; Podolak-Dawidziak M; Lewandowski K; Bator M; Wróbel T
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681577
[TBL] [Abstract][Full Text] [Related]
20. The immune landscape in BCR-ABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy.
Strickland M; Quek L; Psaila B
Br J Haematol; 2022 Mar; 196(5):1149-1158. PubMed ID: 34618358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
